Tear Proteomics in Keratoconus: A Quantitative SWATH-MS Analysis.
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
02 08 2021
02 08 2021
Historique:
entrez:
25
8
2021
pubmed:
26
8
2021
medline:
28
9
2021
Statut:
ppublish
Résumé
To elucidate dysregulated proteins in keratoconus (KC) to provide a better understanding of the molecular mechanisms that lead to the development of the disease using sequential window acquisition of all theoretical mass spectra (SWATH-MS) as a protein quantification tool of the tear proteomic profile. Prospective cross-sectional study that includes 25 keratoconic eyes and 25 healthy eyes. All participants underwent a clinical, tomographic, and aberrometric exam. Tear sample was collected using Schirmer strips and analyzed by liquid chromatography with tandem mass spectrometry. SWATH-MS was used as a quantification tool of the tear proteomic profile. The expression of the quantified proteins was compared between groups, and the biological and molecular functions of the dysregulated proteins as well as their functional relationships were studied by in silico analysis. A total of 203 proteins were quantified in tear samples of patients with KC and control participants, of which 18 showed differential expression between groups (P < 0.05). An increase in the expression of 7 proteins and a decrease in the expression of 11 proteins were observed. Protein-protein interactions and gene ontology analysis showed the involvement of these dysregulated proteins in structural, inflammatory-immune, iron homeostasis, oxidative stress, and extracellular matrix proteolysis processes. Tear protein quantification has revealed the dysregulation of proteins involved in biological processes previously associated with KC. Among them, iron homeostasis should be highlighted as a relevant pathway in the KC pathophysiology, and it should be taken into account in the development of therapeutic targets to cope with tissue damage derived from iron accumulation and toxicity.
Identifiants
pubmed: 34431975
pii: 2776724
doi: 10.1167/iovs.62.10.30
pmc: PMC8399462
doi:
Substances chimiques
Biomarkers
0
Eye Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Références
Acta Ophthalmol. 2021 Sep;99(6):e777-e794
pubmed: 33354927
Mol Cell Proteomics. 2007 Sep;6(9):1638-55
pubmed: 17533153
Cornea. 2021 Mar 1;40(3):334-341
pubmed: 32833845
Ophthalmology. 2005 Apr;112(4):654-9
pubmed: 15808258
DNA Cell Biol. 2002 Apr;21(4):297-306
pubmed: 12042069
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Acta Ophthalmol. 2012 Jun;90(4):e303-9
pubmed: 22413749
Mol Vis. 2015 Apr 25;21:451-60
pubmed: 25999673
Anal Chem. 2009 Oct 1;81(19):7974-80
pubmed: 19743813
Invest Ophthalmol Vis Sci. 2016 Oct 1;57(13):5372-5382
pubmed: 27732724
J Proteomics. 2017 Jan 6;150:359-367
pubmed: 27184738
Invest Ophthalmol Vis Sci. 1996 Apr;37(5):727-39
pubmed: 8603858
Cont Lens Anterior Eye. 2007 Sep;30(4):223-32
pubmed: 17481941
Methods Mol Biol. 2021;2259:105-141
pubmed: 33687711
Eye (Lond). 2010 Aug;24(8):1396-402
pubmed: 20150925
Proteomics. 2015 Aug;15(15):2597-601
pubmed: 25921073
Mol Vis. 2010 Oct 02;16:1949-57
pubmed: 21031023
Br J Ophthalmol. 2009 Jun;93(6):820-4
pubmed: 19304583
Biochim Biophys Acta. 2009 Jul;1790(7):637-49
pubmed: 19059309
Int J Mol Sci. 2021 Feb 15;22(4):
pubmed: 33672065
Eye Vis (Lond). 2016 Sep 02;3(1):22
pubmed: 27595117
Transl Res. 2021 Jan 17;:
pubmed: 33465489
Mol Cell Proteomics. 2011 Jan;10(1):M110.003335
pubmed: 20807836
Mol Vis. 2010 Oct 13;16:2055-61
pubmed: 21042560
Neurobiol Dis. 2016 Oct;94:169-78
pubmed: 27189756
Redox Biol. 2017 Aug;12:8-17
pubmed: 28212525
Biomed Res Int. 2013;2013:247438
pubmed: 24350254
Br J Ophthalmol. 2005 Nov;89(11):1403-6
pubmed: 16234439
Ann Transplant. 2013 May 10;18:205-17
pubmed: 23792522
Exp Eye Res. 2020 Nov;200:108211
pubmed: 32890481
Eye (Lond). 2014 Mar;28(3):285-9
pubmed: 24310241
J Curr Ophthalmol. 2020 Mar 23;32(1):26-31
pubmed: 32510010
Curr Eye Res. 2016 Nov;41(11):1414-1418
pubmed: 27158890
Int J Mol Sci. 2013 Sep 23;14(9):19294-308
pubmed: 24065107
Drug Discov Today. 2005 Feb 15;10(4):267-73
pubmed: 15708745
Eye (Lond). 2011 Sep;25(9):1225-33
pubmed: 21701529
Am J Ophthalmol. 2011 Aug;152(2):157-162.e1
pubmed: 21708379
Ocul Immunol Inflamm. 2019;27(6):942-948
pubmed: 30230940
Exp Eye Res. 2011 Apr;92(4):282-98
pubmed: 21281627
Ophthalmic Physiol Opt. 1998 Mar;18(2):182-6
pubmed: 9692040
Int Ophthalmol. 2015 Aug;35(4):467-72
pubmed: 25062709
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4361-9
pubmed: 18515575
Anal Chem. 1996 Mar 1;68(5):850-8
pubmed: 8779443
Mol Vis. 2007 Jul 24;13:1285-90
pubmed: 17679946
Nat Methods. 2013 Dec;10(12):1239-45
pubmed: 24162924
Invest Ophthalmol Vis Sci. 2006 May;47(5):1902-10
pubmed: 16638997
Curr Eye Res. 1997 Jan;16(1):19-25
pubmed: 9043819
J Biol Chem. 2013 Apr 26;288(17):11649-61
pubmed: 23463506
J Cataract Refract Surg. 1998 Apr;24(4):456-63
pubmed: 9584238
Optom Vis Sci. 2015 Feb;92(2):e35-41
pubmed: 25397925
Mol Vis. 2013 Oct 30;19:2124-34
pubmed: 24194634
Postepy Hig Med Dosw (Online). 2017 May 5;71(0):339-351
pubmed: 28513458
Int J Mol Sci. 2020 Nov 10;21(22):
pubmed: 33182810
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Invest Ophthalmol Vis Sci. 2011 Nov 04;52(12):8592-7
pubmed: 21969298
Mol Aspects Med. 2001 Feb-Apr;22(1-2):1-87
pubmed: 11207374
J Biol Chem. 1993 Feb 5;268(4):2781-92
pubmed: 8428952
Toxicol Appl Pharmacol. 2005 Jan 15;202(2):199-211
pubmed: 15629195
Ocul Immunol Inflamm. 2020 Apr 2;28(3):348-353
pubmed: 31009587
Exp Eye Res. 2012 Mar;96(1):132-7
pubmed: 22197752
Curr Eye Res. 2000 Aug;21(2):662-8
pubmed: 11148603
Int J Antimicrob Agents. 2009 Apr;33(4):301.e1-8
pubmed: 18842395
Graefes Arch Clin Exp Ophthalmol. 2021 Feb;259(2):459-467
pubmed: 32949300